Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 5;8(8):1173.
doi: 10.3390/jcm8081173.

New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer

Hiroshi Imaoka  1 , Mitsuhito Sasaki  2 , Yusuke Hashimoto  2 , Kazuo Watanabe  2 , Masafumi Ikeda  2
Affiliations
Review

New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer

Hiroshi Imaoka et al. J Clin Med. .

Abstract

Pancreatic cancer is a lethal cancer with an increasing incidence. Despite improvements in chemotherapy, patients with pancreatic cancer continue to face poor prognoses. Endoscopic ultrasound-guided tissue acquisition (EUS-TA) is the primary method for obtaining tissue samples of pancreatic cancer. Due to advancements in next-generation sequencing (NGS) technologies, multiple parallel sequencing can be applied to EUS-TA samples. Genomic biomarkers for therapeutic stratification in pancreatic cancer are still lacking, however, NGS can unveil potential predictive genomic biomarkers of treatment response. Thus, the importance of NGS using EUS-TA samples is becoming recognized. In this review, we discuss the recent advances in EUS-TA application for NGS of pancreatic cancer.

Keywords: biomarker; endoscopic ultrasound-guided fine needle aspiration; endoscopic ultrasound-guided fine needle biopsy; endoscopic ultrasound-guided tissue acquisition; genome sequencing; next-generation sequencing; pancreatic cancer; precision medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Linear echoendoscope (GF-UE160, Olympus Medical Systems, Tokyo, Japan).
Figure 2
Figure 2
Representative case of Endoscopic Ultrasound-Guided Tissue Acquisition (EUS-TA) for pancreatic cancer (PC). (A) Endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) of PC located in the body of the pancreas. (B) Tissue sample obtained by EUS-FNB showing large tissue fragments of poorly differentiated adenocarcinoma.
Figure 3
Figure 3
Representative case of EUS-TA for PC. (A) EUS-FNB of PC located in the tail of the pancreas. (B) Tissue sample from primary tumor containing more stromal cells than neoplastic cells. (C) Tissue sample from lymph node metastasis showing higher tumor fraction. This sample ware utilized for next-generation sequencing (NGS).
Figure 4
Figure 4
Differences in needle design between EUS-FNA and EUS-FNB needles.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019;69:7–34. - PubMed
    1. Burris H.A., 3rd, Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. 1997;15:2403–2413. - PubMed
    1. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007;25:1960–1966. - PubMed
    1. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011;364:1817–1825. - PubMed
    1. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., Seay T., Tjulandin S.A., Ma W.W., Saleh M.N., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013;369:1691–1703. - PMC - PubMed

LinkOut - more resources